Qelbree (Viloxazine).
The Newer Non-Stimulant ADHD Option.

Qelbree (viloxazine extended-release) is one of the newer non-stimulant options for ADHD, approved by the FDA in 2021 for pediatric patients and subsequently for adults. It offers a distinct mechanism from both stimulants and from Strattera (atomoxetine), expanding the choices available for people who cannot or do not want to use controlled substances.

What Is Qelbree?

Viloxazine (Qelbree) is a selective norepinephrine reuptake inhibitor (SNRI-like) with additional activity at several serotonin receptors -- including partial agonism at 5-HT2B and antagonism at 5-HT2C. This serotonergic component distinguishes it from atomoxetine (Strattera), which acts almost exclusively on norepinephrine.

FDA-approved for:

• ADHD in children ages 6 to 17 (approved 2021)
• ADHD in adults (approved 2023)

It is not a controlled substance. No abuse potential has been identified. It does not require DEA scheduling or the same prescription logistics as stimulants.

How It Differs from Strattera

Both Qelbree and Strattera are non-stimulant, non-controlled ADHD medications that target norepinephrine and require weeks to reach full effect. The key differences:

• Mechanism: Qelbree has the serotonin receptor activity described above; Strattera does not. This may contribute to modest improvements in mood alongside ADHD symptoms.
• Side effect profile: Qelbree's most common side effect is somnolence (drowsiness), which is counterintuitive for an ADHD medication. Strattera more commonly causes nausea and initial fatigue. Individual responses differ.
• Dosing: Qelbree is available in 100, 150, and 200 mg capsules; adults typically start at 200 mg and may increase to 400 mg. Strattera is weight-based.
• Drug interactions: Qelbree inhibits CYP1A2, which means it can raise blood levels of other medications processed by that enzyme (including some antipsychotics, clozapine, and theophylline). This requires checking for interactions with your other medications.

How Long Does It Take to Work?

Like other non-stimulant ADHD medications, Qelbree requires consistent daily use over weeks before full benefit is seen. Most patients notice some improvement within 2 to 4 weeks; full effect takes up to 6 to 8 weeks. This is different from stimulants, which work on the first dose.

Common Side Effects

• Somnolence / drowsiness -- the most commonly reported side effect, particularly in the first weeks; taking it in the evening may help
• Decreased appetite
• Nausea -- especially early; taking with food helps
• Irritability or mood changes -- particularly during titration
• Fatigue
• Elevated heart rate and blood pressure -- modest; monitor at follow-ups

There is a class warning about suicidal ideation in children and adolescents shared with Strattera and other noradrenergic medications. Clinical monitoring is appropriate in younger patients, especially during the first months.

Who Is Qelbree a Good Fit For?

• Patients who have tried Strattera without success or with intolerable side effects
• ADHD with co-occurring mood or anxiety symptoms that may benefit from the serotonergic component
• Patients who prefer non-controlled medications and want an alternative to Strattera
• Adults with ADHD who have struggled with stimulant access during the ongoing national shortage